Last reviewed · How we verify
NCT06805474
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
trial testing Observational in Macular Degeneration in 30 participants. Currently enrolling.
20 May 2025
Quick facts
| Lead sponsor | Nanoscope Therapeutics Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 28 January 2025 |
| Primary completion | 20 May 2025 |
| Estimated completion | 27 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Observational — full drug profile →
Conditions studied
- Macular Degeneration — all drugs for Macular Degeneration →
- Geographic Atrophy — all drugs for Geographic Atrophy →
- Stargardt Disease — all drugs for Stargardt Disease →
Sponsor
Nanoscope Therapeutics Inc. — full company profile →
Who can join
18 and older, any sex, with Macular Degeneration or Geographic Atrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying aid (eGlasses) and then with eGlasses. These results will be compared to ETDRS testing results for the same participants without eGlasses and then with eGlasses. Two cohorts will consist of participants who have vision loss due to STGD or geographic atrophy (GA) due to age-related macular degenerations (AMD). Normally sighted participants will provide a control group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06805474
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Observational
Trials testing the same drug.
- NCT07356700 — Deciphering the Factors of Longevity Through a Multi-Omics Study in Long-Lived Individuals in Hong Kong · not yet recruiting
- NCT07381751 — Artificial Intelligence-assisted MDS-UPDRS Assessment for Parkinson's Disease · not yet recruiting
- NCT07347574 — NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in HK · not yet recruiting
- NCT07338968 — A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma · not yet recruiting
- NCT06792994 — A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients Wi · not yet recruiting
Other recruiting trials for Macular Degeneration
Currently open trials in the same condition.
- NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
- NCT07085533 — Natural History Study of Inherited Retinal Diseases · recruiting
- NCT06779773 — A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy · recruiting
- NCT06635148 — A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Se · Phase 2 · recruiting
- NCT06717139 — Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD · active not recruiting
Other Nanoscope Therapeutics Inc. trials
Trials by the same sponsor.
- NCT05820100 — Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT · completed
- NCT05417126 — Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease · Phase 2 · completed
- NCT04945772 — Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] · Phase 2 · completed
- NCT04919473 — Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06805474 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanoscope Therapeutics Inc.
- Last refreshed: 24 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06805474.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing